<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Influence of HER2 overexpression and prognosis in esophagogastric cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Influence of HER2 overexpression and prognosis in esophagogastric cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Influence of HER2 overexpression and prognosis in esophagogastric cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Study</td> <td class="subtitle1">Disease stage</td> <td class="subtitle1">Tumor site</td> <td class="subtitle1">n</td> <td class="subtitle1">Treatment</td> <td class="subtitle1">HER2-positive rate (%)</td> <td class="subtitle1">Association with survival: Median OS in HER2-positive versus HER2-negative patients</td> </tr> <tr> <td>AVAGAST<sup>[1]</sup></td> <td class="centered">Metastatic*</td> <td class="centered">Gastric, GEJ</td> <td class="centered">712</td> <td class="centered">FP with and without bevacizumab</td> <td class="centered">NR</td> <td class="centered">Null: 9.8 versus 10.5 months (NSS)<sup>¶</sup></td> </tr> <tr> <td>Europe/USA collaboration<sup>Δ</sup><sup>[2]</sup></td> <td class="centered">Metastatic</td> <td class="centered">Gastric, GEJ</td> <td class="centered">381</td> <td class="centered">Chemotherapy</td> <td class="centered">20</td> <td class="centered">Favorable: 13.9 versus 11.4 months (p = 0.047)<sup>¶</sup></td> </tr> <tr> <td>EXPAND<sup>[3,4]</sup></td> <td class="centered">Metastatic*</td> <td class="centered">Gastric, GEJ</td> <td class="centered">679</td> <td class="centered">FP with and without cetuximab</td> <td class="centered">21</td> <td class="centered"> <p>Favorable in control arm: 14.0 versus 9.7 months (NSS)</p> Favorable in treatment arm: 13.3 versus 9.2 months (NSS)</td> </tr> <tr> <td>REAL3<sup>[5]</sup></td> <td class="centered">Metastatic*</td> <td class="centered">Gastric, GEJ, esophagus</td> <td class="centered">174</td> <td class="centered">EOC with and without panitumumab</td> <td class="centered">16</td> <td class="centered">Null: Details not reported</td> </tr> <tr> <td>ACTS-GC<sup>[6]</sup></td> <td class="centered">Operable</td> <td class="centered">Gastric</td> <td class="centered">829</td> <td class="centered">Surgery with and without S-1</td> <td class="centered">13.6</td> <td class="centered">Null: 5-year OS 64 versus 68% (NSS)<sup>¶</sup></td> </tr> <tr> <td>MAGIC<sup>[7]</sup></td> <td class="centered">Operable</td> <td class="centered">Gastric, GEJ, esophagus</td> <td class="centered">415</td> <td class="centered">Surgery with and without ECF</td> <td class="centered">10.9</td> <td class="centered">Null: Details not reported</td> </tr> <tr> <td>INT0116<sup>[8]</sup></td> <td class="centered">Operable</td> <td class="centered">Gastric, GEJ</td> <td class="centered">258</td> <td class="centered">Surgery with and without chemoradiotherapy</td> <td class="centered">10.9</td> <td class="centered"> <p>Null in control arm: 22 versus 24 months (p = 0.76)</p> Adverse in chemoradiotherapy arm: 16 versus 44 months (p = 0.025)</td> </tr> </tbody></table></div><div class="graphic_footnotes">HER2: human epidermal growth factor receptor 2; OS: overall survival; GEJ: gastroesophageal junction; FP: fluoropyrimidine plus cisplatin; NR: not reported; NSS: not statistically significant; USA: United States of America; EOC: epirubicin, oxaliplatin, and capecitabine; S-1: ftorafur (tegafur), gimeracil, and oteracil; ECF: epirubicin, cisplatin, and fluorouracil.<br/>* Includes locally advanced unresectable.<br/>¶ Analysis combined all patients.<br/>Δ Pooled analysis of six first-line trials utilizing various combinations of fluorouracil, oxaliplatin, cisplatin, and/or docetaxel.</div><div class="graphic_reference">References: 

<ol>
<li>Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30:2119.</li>
<li>Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23:2656.</li>
<li>Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancel Oncol 2013; 14:490.</li>
<li>Lordick F, Kang YK, Salman P, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. J Clin Oncol 2013; 31:abstr 4021.</li>
<li>Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14:481.</li>
<li>Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18:5992.</li>
<li>Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 2013; 24:1253.</li>
<li>Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 2013 [ahead of print].</li></ol></div><div id="graphicVersion">Graphic 89512 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
